Celularity has filed a notice of an exempt offering of securities to raise $9,847,230.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Celularity is raising up to $9,847,230.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Celularity
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularitys innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through natures immunotherapy engine the placenta Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.
To learn more about Celularity, visit https://celularity.com/
Celularity Linkedin Page: https://www.linkedin.com/company/celularity/
Contact:
Robert Hariri, Chief Executive Officer
908-768-2170
https://www.linkedin.com/in/drbobhariri/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
